▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2958 by analyst upside · 2026-09-29
GSK
GSK plc
Healthcare · Market Cap $100B · P/E 15.8x
ANALYST PRICE TARGET
+19.9%
implied upside to consensus target
Current Price $49.7
Consensus Target $59.58
Bull Target $70.0
Bear Target $50.0
Analysts Covering 8
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
2
Hold
4
Sell
1
52-Week Low $40.36
52-Week High $61.7
YTD Return +2.8%
FUNDAMENTALS
Market Cap $100B
P/E Ratio (TTM) 15.8x
Forward P/E 9.9x
EPS (TTM) $3.14
PEG Ratio 6.00
Dividend Yield 3.69%
Revenue (TTM) $33.2B
Profit Margin 14.5%
52-WEEK RANGE
52-Week Low $40.36
52-Week High $61.7
Current Price $49.7
Bear Target $50.0
Bull Target $70.0
● Now $49.7 ● Target $59.58
TRADING DATA
Avg Volume 3.6M
YTD Return +2.8%
Analyst Count 8
Consensus Hold
Upside to Target +19.9%
Last Updated 2026-09-29

ANALYST SUMMARY

GSK plc (GSK) is currently trading at $49.7 with a Wall Street consensus price target of $59.58, implying potential upside of 19.9% over the next 12 months. 8 analysts currently cover GSK, with a consensus rating of Hold - 38% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $70.0, while the most cautious has a target of $50.0.

GSK operates in the Healthcare sector with a market capitalisation of $100B. The stock is up 2.8% year-to-date and is currently trading near the lower end of its 52-week range of $40.36 – $61.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

NVO +19.5%
Novo Nordisk A/S
$171B · P/E 9.7x · Hold
ZTS +34.4%
Zoetis Inc.
$30B · P/E 11.7x · Buy
NVS +6.4%
Novartis AG
$279B · P/E 22.0x · Buy
ILMN -25.5%
Illumina, Inc.
$41B · P/E 50.6x · Buy
GMAB +10.7%
Genmab A/S
$22B · P/E 28.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GSK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↓ Downgrade
Equal-Weight → Underweight 2026-01-06 Building track record
Jefferies ↓ Downgrade
Buy → Hold 2024-11-12 50% win rate (6 calls)
Guggenheim ↓ Downgrade
Buy → Neutral 2024-10-31 62% win rate (8 calls)
UBS ↓ Downgrade
Buy → Neutral 2024-07-08 33% win rate (6 calls)
Jefferies - Reiterated
Buy → Buy 2024-07-02 50% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
17/30
Consensus clarity
22/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →